CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines.

US has announced team up with multinational pharmaceutical companies CSL, GSK, Sanofi, and Seqirus for a $72 million worth of bird flu vaccine production initiative.On Friday, October 4, the US Federal health officials announced that they will

It would more than double the country's supply of shots targeting bird flu, raising the country's total supply of ready-to-use doses to 10 million within the first quarter of 2025. GSK, Sanofi and CSL will also make additional bulk vaccine ingredients matched to circulating strains of bird flu,